Retrospective Observational Research Study to Describe the Real World Use

See also
Status	Clinical Trial	Phase
Completed	`NCT00001637` - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults	Phase 2
Terminated	`NCT00543972` - Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia	Phase 1
Completed	`NCT00521664` - A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups	Phase 3
Completed	`NCT01380756` - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05031897` - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	Phase 2
Terminated	`NCT00126893` - Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia	Phase 1
Completed	`NCT03613727` - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients	Phase 2
Active, not recruiting	`NCT04714372` - FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia	Phase 1
Completed	`NCT02763475` - NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents	Phase 2
Terminated	`NCT01643603` - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies	Phase 1
Completed	`NCT00497991` - Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia	Phase 1
Not yet recruiting	`NCT05787951` - Frequency and Risk Factors of Acute Myeloid Leukemia
Completed	`NCT04628338` - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation	Early Phase 1
Completed	`NCT02719821` - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation	N/A
Active, not recruiting	`NCT00111345` - Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Phase 2/Phase 3
Completed	`NCT00114764` - Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)	Phase 2
Recruiting	`NCT05871008` - Integrated Actionable Aging Assessment for Cancer Patients Pilot	N/A
Recruiting	`NCT03638206` - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	Phase 1/Phase 2
Recruiting	`NCT05035706` - Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors	Early Phase 1
Terminated	`NCT00887926` - Study of IMC-EB10 in Participant With Leukemia	Phase 1

NCT number	NCT05363488
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	October 8, 2021
Completion date	October 8, 2021

Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms